Clinical trials · Missouri
Down Syndrome clinical trials in Missouri
We’re tracking 82 recruiting down syndrome studies with a site in Missouri — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Missouri
- NCT07003100Recruiting
Studying mogamulizumab rash in mycosis fungoides or sezary syndrome
This study looks at a common skin rash caused by the drug mogamulizumab in patients with certain types of lymphoma. It aims to learn more about the rash and how to manage it, so your experience can help future patients.
St Louis, MissouriAges 18 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
City of Saint Peters, MissouriAges 18 years+ - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Kansas City, MissouriAges 6–39 - NCT05432349Recruiting
Rett syndrome genetic registry for MECP2 changes
This trial is a registry that collects health and genetic information from people with Rett syndrome. It may help researchers better understand how MECP2 loss-of-function changes lead to symptoms and how to support patients.
St Louis, MissouriAges birth–99 years - NCT07519395RecruitingPhase 2
Camlipixant for IBS with diarrhea or mixed symptoms
This study tests an investigational drug, camlipixant, to see if it can reduce belly pain and diarrhea or mixed bowel symptoms in adults with irritable bowel syndrome (IBS). If you've tried other IBS treatments without enough relief, this might be an option.
Hazelwood, MissouriAges 18–80 - NCT07478172Recruiting
Electrical muscle stimulation exercise for neuromuscular disease
This study tests whether whole-body electrical muscle stimulation (using small electrodes on the skin) can help adults with certain neuromuscular diseases exercise and improve muscle strength. It may be an option if you can stand for about 15 minutes at a time and have some muscle strength left.
Columbia, MissouriAges 18 years+ - NCT06789913RecruitingPhase 2
Testing RLY-2608 for growth disorders linked to PIK3CA mutations
This trial tests a new medicine, RLY-2608, that targets the specific genetic change (PIK3CA mutation) causing overgrowth conditions. It aims to see if the drug can slow or stop the growth of affected tissues.
St Louis, MissouriAges 2 years+ - NCT06538181RecruitingPhase 1
Testing pacritinib for VEXAS syndrome
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
St Louis, MissouriAges 18 years+ - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Columbia, MissouriAges Up to 22 years - NCT04571658Recruiting
NEPTUNE Match study linking you to possible kidney research trials
This study is an add-on process that uses information from the NEPTUNE kidney study to see whether you might be able to join other kidney research trials. It may help connect eligible people with appropriate new treatment studies when they become available.
Kansas City, MissouriAges 1–80 - NCT07738107RecruitingPhase 1/Phase 2
Study of ATR 1072 for PRKAG2 syndrome
This trial tests a new medicine called ATR 1072 for people with PRKAG2 syndrome, a genetic heart condition. It aims to see if the drug is safe and can help manage symptoms.
Kansas City, MissouriAges 18–65 - NCT07636811RecruitingPhase 2
Mivelsiran for Early Alzheimer's in Down Syndrome
This trial tests a new drug called mivelsiran designed to slow early-stage Alzheimer's disease in adults with Down syndrome. The drug works by targeting amyloid, a protein that builds up in the brain and causes cognitive decline.
St Louis, MissouriAges 40–55 - NCT07625579Recruiting
Collaboration for Down Syndrome Progress Research Study
This research study aims to better understand Down syndrome by collecting health information, family history, and sometimes brain imaging or sleep data from children and adults with Down syndrome and their families. The goal is to advance knowledge that could improve health and development for people with Down syndrome.
St Louis, MissouriAges Any age - NCT07607730Recruiting
Group therapy for emotion control in teens with Prader-Willi syndrome
This study tests a group therapy program designed to help teenagers with Prader-Willi syndrome (a genetic condition) learn better emotional control and regulation skills. Your teen and family would attend weekly group sessions to practice tools for managing emotions like anger or frustration.
Kansas City, MissouriAges 13–17 - NCT07450664Enrolling by invitation
Observational study of VYKAT XR for Prader-Willi syndrome
This study follows people with Prader-Willi syndrome who are already taking or starting VYKAT XR, including those switching from an earlier version of the drug (DCCR). It aims to understand how the treatment works in everyday life.
Kansas City, MissouriAges 4 years+ - NCT07422480RecruitingPhase 3
Comparing elritercept to epoetin alfa for anemia in MDS needing transfusions
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Kansas City, MissouriAges 18 years+ - NCT06196203RecruitingPhase 2
Study of AK117 with Azacitidine for High-Risk MDS
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
St Louis, MissouriAges 18 years+ - NCT06850038Recruiting
Long-term study of odevixibat in Alagille syndrome
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
Kansas City, MissouriAges Any age - NCT06834594RecruitingPhase 4
Bleeding patterns in teens with Turner syndrome on progesterone
This study looks at how different ways of taking progesterone (a hormone given along with estrogen) affect bleeding patterns in teens with Turner syndrome. The goal is to find the best hormone schedule to cause regular, predictable periods.
Kansas City, MissouriAges 12–20 - NCT06747949RecruitingPhase 3
Long term extension study of dazodalibep for Sjogren's syndrome
This study gives continued access to the study drug dazodalibep for people with Sjogren's syndrome who completed a prior phase 3 study. The goal is to see how safe and effective the medication is over a longer period.
Kansas City, MissouriAges 18 years+ - NCT06641414RecruitingPhase 3
Lisaftoclax with azacytidine for higher-risk myelodysplastic syndrome
This trial tests a new drug called lisaftoclax combined with a standard treatment, azacytidine, for people newly diagnosed with higher-risk myelodysplastic syndrome (MDS). The goal is to see if the combination helps control the disease better than what's currently available.
St Louis, MissouriAges 18 years+ - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Farmington, MissouriAges 18 years+ - NCT06529731RecruitingPhase 2
Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT06499285RecruitingPhase 3
Study of a new drug to treat anemia in adults with low to intermediate risk MDS who need transfusions
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
Kansas City, MissouriAges 18 years+
Down Syndrome trials by city in Missouri
Where these studies are running in Missouri
Institutions with a site for the recruiting down syndrome studies listed above.
- Washington University in St. Louis · 8 studies
- Children's Mercy Hospital · 5 studies
- SSM Health Cardinal Glennon Children's Hospital · 2 studies
- American Oncology Partners P.A. MidAmerica Cancer Care
- Ascentage Investigative Site
- Children's Mercy Kansas City
- Clinical Trial Site
- GSK Investigational Site
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Down Syndrome trials in other states
Common questions
- Are there down syndrome clinical trials in Missouri?
- Yes. We're currently tracking 82 recruiting down syndrome studies with a site in Missouri, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study in Missouri?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Missouri to take part?
- Not necessarily. These studies have a site in Missouri, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open in Missouri regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.